New directions in metabolic syndrome diagnosis: assessment of vascular endothelial growth factor, pentraxin-3 and transforming growth factor beta levels
https://doi.org/10.15829/1728-8800-2019-6-57-61
Abstract
The article presents the results of Russian and international clinical studies on the levels of angiogenesis markers (vascular endothelial growth factor, pentraxin 3 and transforming growth factor beta) in patients with metabolic syndrome.
About the Authors
R. N. Shepel
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
Moscow.
O. M. Drapkina
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
Moscow.
References
1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009;120(16):1640-5. doi:10.1161/CIRCULATIONAHA.109.192644.
2. Alberti KG, Zimmet P. The metabolic syndrome — a new worldwide definition. The Lancet. 2005; 366(9491 ):1059-62. doi:10.1016/S0140-6736(05)67402-8.
3. Mychka VB, Zhernakova YuV, Chazova IYe. Society of Cardiology of the Russian Federation: Guidelines on diagnosis and treatment of the metabolic syndrome (2nd revision). Pract Med. 2010;3(54): 15-8. (In Russ.)
4. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162. doi:10.1155/2014/943162.
5. Delavari A, Forouzanfar MH, Alikhani S, et al. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care. 2009; 32(6):1092-7 doi:10.2337/dc08-1800.
6. Metelskaya VA, Shkolnikova MA, Shalnova SA, et al. Prevalence, components, and correlates of metabolic syndrome (MetS) among elderly Muscovites. Arch Gerontol Geriatr. 2012;55(2):231-7 doi:10.1016/j.archger.2011.09.005.
7. Shavshin DA, Rotar OP, Solntsev VN, et al. The prevalence of metabolic syndrome in a sample of residents of Kaliningrad. Arterial'naya Gipertenziya = Arterial Hypertension. 2015;21(6):630-8. (In Russ.) doi:10.18705/1607-419X-2015-21-6-630-638.
8. Voevoda MI, Koval'kova NA, Ragino Yul, et al. Prevalence of metabolic syndrome in 29. Novosibirsk residents aged 25 to 45 years. Ter archiev. 2016;88(10):51-6. (In Russ.) doi:10.17116/terarkh2016881051-56.
9. Wilson PWF, Kannel WB, Silbershatz H, DAgostino RB. Clustering of metabolic factors and coronary heart disease. Archives of Internal Medicine. 1999;159(10):1104-9. doi:10.1001/archinte.159.10.1104.
10. Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27(3):788-93. doi:10.2337/diacare.27.3.788.
11. Srikanthan K, Feyh A, Visweshwar H, et al. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci. 2016;13(1):25-38. doi:10.7150/ijms.13800.
12. Soares R, Costa C. Oxidative stress, inflammation and angiogenesis in the metabolic syndrome. Springer. Heidelberg, Germany, 2009. ISBN: 978-1-4020-9701-0. doi:10.1007/978-1-4020-9701-0.
13. Miyazono K, Usuki K, Heldin CH. Platelet-derived endothelial cell growth factor. Prog Growth Factor Res. 1991;3:207-17.
14. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-8. doi:10.1038/35025215.
15. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159-78. doi:10.1016/j.cytogfr.2005г.01.004.
16. Ohnishi T, Daikuhara Y. Hepatocyte growth facto r/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Biol. 2003;48:797-804. doi:10.1016/s0003-9969(03)00180-8.
17. Zafar MI, Mills K, Ye X, et al. Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis. Diabetol Metab Syndr. 2018;10:62. doi: 10.1186/s13098-018-0363-0.
18. Elias I, Franckhauser S, Ferre T, et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes. 2012;61:1801-13. doi:10.2337/db11-0832.
19. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia. 2003;46:1483-8. doi:10.1007/s00125-003-1221-6.
20. Garcia de la Torre N, Rubio MA, BordiC E, et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008;93:4276-81. doi:10.1210/jc.2007-1370.
21. Gomez-Ambrosi J, Catalan V, Rodriguez A, et al. Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans. J Nutr Biochem. 2010;21:774-80. doi:10.1016/j.jnutbio.2009.05.004.
22. Tinahones FJ, Coin-Araguez L, Mayas MD, et al. Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels. BMC Physiol. 2012;12:4. doi:10.1186/1472-6793-12-4.
23. Robciuc MR, Kivela R, Williams IM, et al. VEGFB/VEGFR1-induced expansion of adipose vasculature counteracts obesity and related metabolic complications. Cell Metab. 2016;23:712-24. doi:10.1016/j.cmet.2016.03.004.
24. Lijnen HR, Christiaens V, Scroyen I, et al. Impaired adipose tissue development in mice with inactivation of placental growth factor function. Diabetes. 2006;55:2698-704. doi:10.2337/db06-0526.
25. Pervanidou P, Chouliaras G, Akalestos A, et al. Increased placental growth factor (PlGF) concentrations in children and adolescents with obesity and the metabolic syndrome. Hormones (Athens). 2014;13(3):369-73. doi:10.14310/horm.2002.1491.
26. Siervo M, Ruggiero D, Sorice R, et al. Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome. J Intern Med. 2010;268:338-47. doi:10.1111/j.1365-2796.2010.02255.x.
27. Siervo M, Ruggiero D, Sorice R, et al. Body mass index is directly associated with biomarkers of angiogenesis and inflammation in children and adolescents. Nutrition. 2012;28:262-6. doi:10.1016/j.nut.2011.06.007.
28. Wada H, Satoh N, Kitaoka S, et al. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis. 2010;208:512-7. doi:10.1016/j.atherosclerosis.2009.07.045.
29. Petrovic D, Verhovec R, Globocnik Petrovic M, et al. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology. 2007;107:291-5. doi:10.1159/000099064.
30. Lin TH, Wang CL, Su HM, et al. Functional vascular endothelial growth factor gene polymorphisms and diabetes: Effect on coronary collaterals in patients with significant coronary artery disease. Clin Chim Acta. 2010;411:1688-93. doi:10.1016/j.cca.2010.07.002.
31. Kim YR, Hong SH. Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome. Biomed Rep. 2015;3(3):319-26. doi:10.3892/br.2015.423.
32. Karakas MF, Buyukkaya E, Kurt M, et al. Serum pentraxin-3 levels are associated with the severity of metabolic syndrome. Med Princ Pract. 2013;22(3):274-9. doi:10.1159/000343904.
33. Zanetti M, Bosutti A, Ferreira C, et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009;9(3):243-8. doi:10.1007/s10238-009-0039-z.
34. Kardas F, Akin L, Kurtoglu S, et al. Plasma Pentraxin 3 as a biomarker of metabolic syndrome. Indian J Pediatr. 2015;82(1):35-8. doi:10.1007/s12098-014-1542-0.
35. Gurel H, Genc H, Celebi G, et al. Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2016;20(20):4305-12.
36. Ozturk K, Kurt O, Dogan T, et al. Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract. 2016;2016:1417962. doi:10.1155/2016/1417962.
37. Lee R, Ahn HR, Shin MH, et al. Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study. J Atheroscler Thromb. 2019 Jan 23 [Epub ahead of print]. doi:10.5551/jat.47167.
38. Miyazaki T, Chiuve S, Sacks FM, et al. Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. PLoS One. 2014;9(4):e94073. doi:10.1371/journal.pone.0094073.
39. Castaneda A, Jauregui-Maldonado E, Ratnani I, et al. Correlation between metabolic syndrome and sleep apnea. World J Diabetes. 2018;9(4):66-71. doi:10.4239/wjd.v9.i4.66.
40. Nabrdalik К, Chodkowski А, Bartman W, et al. Pentraxin 3 and atherosclerosis among type 2 diabetic patients. Open Life Sciences. 2016;12(1):92-8. doi:10.1016/j.diabres.2012.11.020.
41. Lin E, Kuo PH, Liu YL, et al. Transforming growth factor-в signaling pathway-associated genes SMAD2 and TGFBR2 are implicated in metabolic syndrome in a Taiwanese population. Scientific Reports 2017;7:13589. doi:10.1038/s41598-017-14025-4.
42. Yadav H, Quijano C, Kamaraju AK, et al. Protection from obesity and diabetes by blockade of TGF-p/Smad3 signaling. Cell Metab. 2011;14(1):67-79. doi:10.1016/j.cmet.2011.04.013.
43. Mendes NF, Gaspar JM, Lima-JCnior JC, et al. TGF-P1 down-regulation in the mediobasal hypothalamus attenuates hypothalamic inflammation and protects against diet-induced obesity. Metabolism. 2018;85:171-82. doi:10.1016/j.metabol.2018.04.005.
44. Rosmond R, Chagnon M, Bouchard C, et al. Increased abdominal obesity, insulin and glucose levels in nondiabetic subjects with a T29C polymorphism of the transforming growth factor-Pgene. Hormone Research. 2003;59(4): 191-4. doi:10.1159/000069323.
45. Samad F, Yamamoto К, Pandey М, et al. Elevated expression of transforming growth factor-в in adipose tissue from obese mice. Molecular Medicine. 1997;3(1):37-48.
46. Raju J, Bajaj G, Chrusch J, et al. Obese state leads to elevated levels of TGF-в and COX isoforms in platelets of Zucker rats. Molecular and Cellular Biochemistry. 2006;284(1-2):19-24. doi:10.1007/s11010-005-9008-3.
47. Sciarretta S, Ferrucci A, Ciavarella GM, et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens. 2007;20(7):784-91. doi:10.1016/j.amjhyper.2007.01.023.
48. Herder С, Zierer А, Koenig W, et al. Transforming growth factor^ and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002. Diabetes Care. 2009;32(10):1921-3. doi:10.2337/dc09-0476.
Review
For citations:
Shepel R.N., Drapkina O.M. New directions in metabolic syndrome diagnosis: assessment of vascular endothelial growth factor, pentraxin-3 and transforming growth factor beta levels. Cardiovascular Therapy and Prevention. 2019;18(6):57-61. (In Russ.) https://doi.org/10.15829/1728-8800-2019-6-57-61
Views:
799
Email this article 
